Together, our findings indicate that specific-activated Treg subsets are expanded in patients with advanced disease and increase in the frequency of this subset among CD4+ T cells is associated with the TTM indicator of the tumour mass within all major body compartments in patients before therapy. Here, CD4 is linked to neoplasm.